On December 17, Gelonghui reported that Chengda Pharmaceutical (301201.SZ) stated in a recent investor relations activity that the Active Pharmaceutical Ingredient L-carnitine has been approved by the regulatory authorities of several countries and obtained the CEP certification in Europe, covering quality system certification for major global markets. The Active Pharmaceutical Ingredient Brinfido has been approved by South Korea's MFDS, while the Active Pharmaceutical Ingredients Aflibercept and Rivaroxaban are in the process of registration. The Active Pharmaceutical Ingredient Daglizhuo passed CDE approval in November 2024, further enriching the company's product line.
诚达药业(301201.SZ)：艾拉戈克钠、利伐沙班等原料药正在申报注册中
Chengda Pharmaceutical (301201.SZ): Active Pharmaceutical Ingredients such as Edaravone Sodium and Rivaroxaban are currently under registration application.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
In 【2024.11】, surged more than 0.04 million times, achieving the title of stock god Buffett! How do you view Berkshire's performance?
When it comes to legendary figures in the investment world, the name of Warren Buffett, the helm of Berkshire Hathaway, is definitely unavoidable. $Berkshire Ha
【November 2024】Has disney's predicament turned around? Pay attention to these 3 performance signals.
As the entertainment kingdom for nearly a century, Disney's status in Hollywood has gained prominence. Over 60 years of listing on the U.S. stock market, Disney